Roble Belko & Company’s Moderna MRNA Stock Holding History

Roble Belko & Company’s Portfolio MRNA Stock Details MRNA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-150	Closed	-$27K	–	315
2022 Q4	$27K	Buy	+150	New	+$24.5K	0.01%	191

Other funds holding MRNA

Baillie Gifford & Co Edinburgh, United Kingdom $97.9B AUM 20.73% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Flagship Pioneering Cambridge, Massachusetts $1.16B AUM 67.93% 1-Year Est. Return

Coatue Management New York $29.1B AUM 96.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Theleme Partners London, United Kingdom $1.5B AUM 19.72% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Roble Belko & Company's MRNA Position: Q1 2023 in Review

Roble Belko & Company sold out of Moderna (MRNA) in Q1 2023, closing a stake of 150 shares — an estimated $27K sold.

Roble Belko & Company first reported a position in MRNA in Q4 2022 and held it in 1 quarter. The position peaked at $27K in Q4 2022. 1,015 funds tracked by Wall St. Rank hold MRNA as of Q1 2023.

Roble Belko & Company reported no remaining Moderna position as of Q1 2023 after selling out during the quarter.
Roble Belko & Company sold 150 Moderna shares in Q1 2023, an estimated $27K.
Roble Belko & Company first reported a position in Moderna in Q4 2022 and held it in 1 quarter.
Roble Belko & Company's Moderna position peaked at $27K in Q4 2022.
1,015 funds tracked by Wall St. Rank held Moderna as of Q1 2023.

Based on Roble Belko & Company's 13F filing for Q1 2023, filed 10 May 2023.